New pill could tame lung inflammation in sarcoidosis
NCT ID NCT06205121
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests an experimental oral drug called OATD-01 for people with active pulmonary sarcoidosis, a condition causing lung inflammation. About 96 adults will receive either the drug or a placebo for 12 weeks to see if it reduces disease activity measured by PET scans. The goal is to control the disease, not cure it, and participants may need ongoing treatment afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Molecure Investigative Site
WITHDRAWNBirmingham, Alabama, 35209, United States
-
Molecure Investigative Site
WITHDRAWNKansas City, Kansas, 66062, United States
-
Molecure Investigative Site
RECRUITINGBaltimore, Maryland, 21224, United States
-
Molecure Investigative Site
WITHDRAWNRochester, Minnesota, 55905, United States
-
Molecure Investigative Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Molecure Investigative Site
RECRUITINGPhiladelphia, Pennsylvania, 19140, United States
-
Molecure Investigative Site
RECRUITINGCharleston, South Carolina, 29425, United States
-
Molecure Investigative Site
WITHDRAWNVejle, 7100, Denmark
-
Molecure Investigative Site
WITHDRAWNBobigny, 93000, France
-
Molecure Investigative Site
RECRUITINGMontpellier, 34295, France
-
Molecure Investigative Site
RECRUITINGParis, 75013, France
-
Molecure Investigative Site
RECRUITINGParis, 75015, France
-
Molecure Investigative Site
RECRUITINGEssen, 45239, Germany
-
Molecure Investigative Site
RECRUITINGFreiburg im Breisgau, 79106, Germany
-
Molecure Investigative Site
RECRUITINGMainz-GE, 55131, Germany
-
Molecure Investigative Site
WITHDRAWNCorfu, 49100, Greece
-
Molecure Investigative Site
RECRUITINGHeraklion, 71500, Greece
-
Molecure Investigative Site
RECRUITINGPátrai, 26500, Greece
-
Molecure Investigative Site
RECRUITINGThessaloniki, 57010, Greece
-
Molecure Investigative Site
RECRUITINGNieuwegein, 3435 CM, Netherlands
-
Molecure Investigative Site
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Molecure Investigative Site
RECRUITINGBergen, 5009, Norway
-
Molecure Investigative Site
RECRUITINGOslo, 1478, Norway
-
Molecure Investigative Site
RECRUITINGBirmingham, B15 2GW, United Kingdom
-
Molecure Investigative Site
WITHDRAWNCambridge, CB2 0AY, United Kingdom
-
Molecure Investigative Site
RECRUITINGEdinburgh, EH16 4SA, United Kingdom
-
Molecure Investigative Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Molecure Investigative Site
RECRUITINGLondon, SW3 6JY, United Kingdom
Conditions
Explore the condition pages connected to this study.